Balyasny Asset Management
GH icon

Balyasny Asset Management’s Guardant Health GH Stock Holding History

Balyasny Asset Management’s Portfolio GH Stock Details GH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,600
Closed -$3.43M – 3121
2025
Q4 		$3.43M Buy
33,600
+14,100
+72% +$1.26M ﹤0.01% 1593
2025
Q3 		$1.22M Sell
19,500
-10,400
-35% -$566K ﹤0.01% 2036
2025
Q2 		$1.56M Buy
+29,900
New +$1.34M ﹤0.01% 1861
2025
Q1 		– Sell
-6,900
Closed -$211K – 2962
2024
Q4 		$211K Sell
6,900
-91,200
-93% -$2.57M ﹤0.01% 2514
2024
Q3 		$2.25M Buy
+98,100
New +$2.78M ﹤0.01% 1618
2022
Q4 		– Sell
-110,400
Closed -$5.94M – 2940
2022
Q3 		$5.94M Buy
110,400
+85,400
+342% +$4.38M 0.02% 914
2022
Q2 		$1.01M Sell
25,000
-329,000
-93% -$16.3M ﹤0.01% 1745
2022
Q1 		$23.4M Buy
354,000
+340,000
+2,429% +$23.3M 0.07% 365
2021
Q4 		$1.4M Buy
+14,000
New +$1.45M ﹤0.01% 1359

Other funds holding GH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's GH Position: Q1 2026 in Review

Balyasny Asset Management sold out of Guardant Health (GH) in Q1 2026, closing a stake of 505,608 shares — an estimated $51.6M sold.

Balyasny Asset Management first reported a position in GH in Q2 2020 and held it in 20 quarters. The position peaked at $53.4M in Q1 2022. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • Balyasny Asset Management reported no remaining Guardant Health position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 505,608 Guardant Health shares in Q1 2026, an estimated $51.6M.
  • Balyasny Asset Management first reported a position in Guardant Health in Q2 2020 and held it in 20 quarters.
  • Balyasny Asset Management's Guardant Health position peaked at $53.4M in Q1 2022.
  • 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.